Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9624
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWhite, K Len
dc.contributor.authorWiley, J Sen
dc.contributor.authorFrost, Ten
dc.contributor.authorMcKendrick, J Jen
dc.contributor.authorHermann, R Pen
dc.contributor.authorSeldon, Men
dc.contributor.authorEnno, Aen
dc.contributor.authorBell, Ren
dc.contributor.authorBunce, Ien
dc.contributor.authorTaylor, Ken
dc.date.accessioned2015-05-15T22:47:23Z
dc.date.available2015-05-15T22:47:23Z
dc.date.issued1992-10-01en
dc.identifier.citationAustralian and New Zealand Journal of Medicine; 22(5): 449-54en
dc.identifier.govdoc1445034en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9624en
dc.description.abstractAll-trans-retinoic acid (ATRA) is known to induce differentiation of promyelocytes in vitro and also to induce remission of acute promyelocytic leukaemia in vivo. We treated 11 patients with poor prognosis acute promyelocytic leukaemia (APL) with ATRA and obtained seven complete and one partial remission. Remissions took one to three months to achieve and were associated with adverse effects including dry skin and bone pain. In eight patients the white cell count rose above 20 x 10(9)/L within the first ten days of retinoic acid treatment and this was associated with the development of pulmonary leukostasis in three patients which was fatal in one. Another two patients died of intracranial haemorrhage also within the first ten days. ATRA is a promising new agent in the induction therapy of this particular category of acute leukaemia.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAustraliaen
dc.subject.otherCell Differentiation.drug effectsen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherLeukemia, Promyelocytic, Acute.blood.drug therapy.pathologyen
dc.subject.otherLeukocyte Counten
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherRemission Inductionen
dc.subject.otherTretinoin.adverse effects.therapeutic useen
dc.titleAll-trans retinoic acid in the treatment of acute promyelocytic leukaemia.en
dc.typeJournal Articleen
dc.identifier.journaltitleAustralian and New Zealand Journal of Medicineen
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin Hospital, Melbourne, Victoria, Australiaen
dc.description.pages449-54en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1445034en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.